18F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value
- PMID: 29943313
- DOI: 10.1007/s11604-018-0755-y
18F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value
Abstract
Purpose: This study aimed to explore the clinical and prognostic significance of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in epithelial ovarian cancer (EOC).
Methods: We retrospectively investigated 48 EOC patients who underwent preoperative 18F-FDG PET/CT and primary cytoreductive surgery at our hospital between January 2010 and June 2015. None of these patients received neoadjuvant chemotherapy. PET/CT parameters including the maximum and average standardized uptake value (SUVmax, SUVavg), the metabolic tumor volume (MTV) were measured. Tumor proliferation marker Ki67 was evaluated using immunohistochemistry. The relationships between the PET/CT parameters and chemosensitivity, tumor proliferation, and overall survival (OS) were analyzed, respectively.
Results: The median (range) SUVmax, SUVavg, and MTV values were 11.42 (3.14-20.20), 4.8 (2.55-9.47), and 150.11 (0.19-792.46), respectively. Overall, 93.8% (45/48) of patients had high-grade serous ovarian cancer. The SUVmax value had a positive correlation with the Ki67 index (P = 0.030, r = 0.314), and a higher SUVmax level was associated with chemosensitivity (P = 0.026). However, neither SUVavg nor MTV had associations with the patients' clinicopathological parameters. None of these three PET/CT parameters were found to be potential predictors of OS.
Conclusions: Preoperative 18F-FDG PET/CT had a predictive value on chemosensitivity and proliferation after primary debulking surgery in EOC patients noninvasively.
Keywords: 18F-FDG PET/CT; Chemosensitivity; Epithelial ovarian cancer; Maximum standardized uptake value; Proliferation.
Similar articles
-
Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.Gynecol Oncol. 2015 Mar;136(3):498-504. doi: 10.1016/j.ygyno.2014.12.032. Epub 2014 Dec 31. Gynecol Oncol. 2015. PMID: 25557270
-
18F-FDG PET/CT as predictor of tumour biology and prognosis in epithelial ovarian carcinoma.Rev Esp Med Nucl Imagen Mol. 2017 Jul-Aug;36(4):233-240. doi: 10.1016/j.remn.2017.01.004. Epub 2017 Mar 9. Rev Esp Med Nucl Imagen Mol. 2017. PMID: 28284928 English, Spanish.
-
Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer.Eur Radiol. 2017 Jan;27(1):16-23. doi: 10.1007/s00330-016-4368-5. Epub 2016 Apr 27. Eur Radiol. 2017. PMID: 27121932
-
Impact of FDG-PET and -PET/CT imaging in the clinical decision-making of ovarian carcinoma: an evidence-based approach.Womens Health (Lond). 2012 Mar;8(2):191-203. doi: 10.2217/whe.11.91. Womens Health (Lond). 2012. PMID: 22375721 Review.
-
Evaluation of the Prognostic Value of FDG PET/CT Parameters for Patients With Surgically Treated Head and Neck Cancer: A Systematic Review.JAMA Otolaryngol Head Neck Surg. 2020 May 1;146(5):471-479. doi: 10.1001/jamaoto.2020.0014. JAMA Otolaryngol Head Neck Surg. 2020. PMID: 32215611
Cited by
-
Correlation analysis between the SUVmax of FDG-PET/CT and clinicopathological characteristics in oral squamous cell carcinoma.Dentomaxillofac Radiol. 2019 Jul;48(5):20180416. doi: 10.1259/dmfr.20180416. Epub 2019 Mar 5. Dentomaxillofac Radiol. 2019. PMID: 30794427 Free PMC article.
-
EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA).Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3286-3302. doi: 10.1007/s00259-021-05450-9. Epub 2021 Jul 3. Eur J Nucl Med Mol Imaging. 2021. PMID: 34215923
-
The role of 18F-FDG PET/CT-based quantitative metabolic parameters in patients with ovarian clear cell carcinoma.Cancer Biomark. 2020;27(2):189-194. doi: 10.3233/CBM-190904. Cancer Biomark. 2020. PMID: 31796665 Free PMC article.
-
18F-FDG PET/MRI Image of Skin Metastasis of Ovarian Cancer.Mol Imaging Radionucl Ther. 2023 Jun 20;32(2):159-161. doi: 10.4274/mirt.galenos.2022.97268. Mol Imaging Radionucl Ther. 2023. PMID: 37337862 Free PMC article.
-
Current update on malignant epithelial ovarian tumors.Abdom Radiol (NY). 2021 Jun;46(6):2264-2280. doi: 10.1007/s00261-021-03081-0. Epub 2021 Jun 5. Abdom Radiol (NY). 2021. PMID: 34089360 Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical